Understanding how immune responses can help treat resistant prostate cancer

Leveraging PMN immune response to overcome ADT resistance in bone metastatic prostate cancer

NIH-funded research University of Nebraska Medical Center · NIH-10897051

This study is looking at how certain immune cells in the blood of men with advanced prostate cancer respond to the disease, especially in the bones, to understand how their function changes over time and how treatment affects them, with the goal of finding better ways to fight the cancer.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Nebraska Medical Center NIH-funded
Lab location1 site (Omaha, United States)
Project IDNIH-10897051 on NIH RePORTER

What this research studies

This research investigates the immune response of polymorphonuclear leukocytes (PMNs) in patients with metastatic castration-resistant prostate cancer (mCRPC), particularly focusing on how these immune cells interact with the cancer in the bone environment. The study aims to identify the changes in PMN function as the disease progresses and how androgen deprivation therapy (ADT) affects these immune responses. By analyzing blood samples from patients at various stages of prostate cancer, the research seeks to uncover mechanisms of resistance to treatment and develop new therapeutic strategies.

Who could benefit from this research

Good fit: Ideal candidates for this research include men diagnosed with metastatic castration-resistant prostate cancer, particularly those who have undergone androgen deprivation therapy.

Not a fit: Patients with localized prostate cancer or those who have not received androgen deprivation therapy may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved treatment options for patients with advanced prostate cancer who currently have limited effective therapies.

How similar studies have performed: Previous research has shown promising results in understanding immune responses in cancer treatment, suggesting that this approach may yield valuable insights.

Where this research is happening

Omaha, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.